Telcagepant (INN; development code MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co.
Telcagepant (INN; development code MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co.
In the acute treatment of migraine, it was found to have equal efficacy to rizatriptan and zolmitriptan.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).